In Battle Against Alzheimer’s, This May Be Ground Zero

Roche drug trial in Colombia focuses on extended family whose members are likely to carry a gene that can lead to dementia by age 45.

The Wall Street Journal profiles Colombia as the place for a landmark trial for a new drug against dementia. 

"The study, funded by Roche’s U.S. unit, Genentech, along with the U.S. National Institutes of Health and an arm of Banner Alzheimer’s Institute in Phoenix, is one the drug industry’s last big attempts to test a long-held theory: that a buildup of amyloid plaque in the brain is the main cause of Alzheimer’s. The hope is that Roche’s drug can block or slow the process of amyloid formation, or the chain of events that triggers it."